These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 3511292)

  • 1. Nephrogenic adenoma associated with intravesical bacillus Calmette-Guerin treatment: a report of 2 cases.
    Stilmant MM; Siroky MB
    J Urol; 1986 Feb; 135(2):359-61. PubMed ID: 3511292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nephrogenic adenoma in a patient with transitional cell carcinoma of the bladder receiving intravesical bacillus Calmette-Guérin.
    Oyama N; Tanase K; Akino H; Mori H; Kanamaru H; Okada K
    Int J Urol; 1998 Mar; 5(2):185-7. PubMed ID: 9559850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder.
    Herr HW; Pinsky CM; Whitmore WF; Sogani PC; Oettgen HF; Melamed MR
    J Urol; 1986 Feb; 135(2):265-7. PubMed ID: 3511284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacillus Calmette-Guerin for superficial transitional cell carcinoma of the bladder.
    Schellhammer PF; Ladaga LE; Fillion MB
    J Urol; 1986 Feb; 135(2):261-4. PubMed ID: 3511283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of purified protein derivative skin test and granuloma formation in patients treated with intravesical bacillus Calmette-Guerin.
    Kelley DR; Haaff EO; Becich M; Lage J; Bauer WC; Dresner SM; Catalona WJ; Ratliff TL
    J Urol; 1986 Feb; 135(2):268-71. PubMed ID: 3511285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder.
    Haaff EO; Dresner SM; Ratliff TL; Catalona WJ
    J Urol; 1986 Oct; 136(4):820-4. PubMed ID: 3761438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravesical bacillus Calmette-Guerin therapy and associated granulomatous renal masses.
    Stanisic TH; Brewer ML; Graham AR
    J Urol; 1986 Feb; 135(2):356-8. PubMed ID: 3511291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results.
    Kelley DR; Ratliff TL; Catalona WJ; Shapiro A; Lage JM; Bauer WC; Haaff EO; Dresner SM
    J Urol; 1985 Jul; 134(1):48-53. PubMed ID: 3892051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complications of bacillus Calmette-Guerin immunotherapy in 1,278 patients with bladder cancer.
    Lamm DL; Stogdill VD; Stogdill BJ; Crispen RG
    J Urol; 1986 Feb; 135(2):272-4. PubMed ID: 3511286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tubercular prostatic abscess as a complication of intravesical bacillus Calmette-Guérin immunotherapy.
    Aust TR; Massey JA
    Int J Urol; 2005 Oct; 12(10):920-1. PubMed ID: 16323989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nephrogenic adenoma of the bladder after intravesical bacillus Calmette-Guérin treatment.
    Kilciler M; Tan O; Ozgök Y; Tahmaz L; Deveci S; Erduran D
    Urol Int; 2000; 64(4):229-32. PubMed ID: 10895092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bladder cancer immunotherapy.
    Lamm DL; Thor DE; Stogdill VD; Radwin HM
    J Urol; 1982 Nov; 128(5):931-5. PubMed ID: 6757467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.
    Lamm DL; DeHaven JI; Shriver J; Sarosdy MF
    J Urol; 1991 Apr; 145(4):738-40. PubMed ID: 2005691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A nephrogenic adenoma during treatment with intravesical BCG].
    Fariña LA; Laguna P; Palou Redorta J; Algaba F; Santaularia JM; Vicente J
    Arch Esp Urol; 1992 Mar; 45(2):153-4. PubMed ID: 1567259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long term protection in bladder cancer following intralesional immunotherapy.
    Reichert DF; Lamm DL
    J Urol; 1984 Sep; 132(3):570-3. PubMed ID: 6381762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bacillus Calmette-Guérin strain differences as the basis for immunotherapies against bladder cancer.
    Miyazaki J; Onozawa M; Takaoka E; Yano I
    Int J Urol; 2018 May; 25(5):405-413. PubMed ID: 29506322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors.
    Eto M; Koga H; Noma H; Yamaguchi A; Yoshikai Y; Naito S
    Urol Int; 2005; 75(2):114-8. PubMed ID: 16123563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bacillus Calmette-Guerin immunotherapy for bladder cancer.
    Lamm DL
    J Urol; 1985 Jul; 134(1):40-7. PubMed ID: 3892050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor.
    Coplen DE; Marcus MD; Myers JA; Ratliff TL; Catalona WJ
    J Urol; 1990 Sep; 144(3):652-7. PubMed ID: 2388321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are cystoscopy and urinary cytology sufficient to identify candidates for subsequent biopsy after bacillus Calmette-Guérin treatment in patients with bladder carcinoma in situ?
    Haase RN; Harving N
    Scand J Urol; 2015; 49(4):338-40. PubMed ID: 25660358
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.